Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alveus Therapeutics Inc

Di cosa scriviamo

Annunci EconomiciFinanzaMedicina Salute Benessere

5 comunicati stampa

Guarda tutti i comunicati
14/09/2026
Medicina Salute Benessere
Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management
Fonte
Alveus Therapeutics Inc
Emittente
GLOBENEWSWIRE
1.00
0
01/09/2026
Medicina Salute Benessere
Alveus Therapeutics Strengthens Executive Leadership Team, Opens Boston office
Fonte
Alveus Therapeutics Inc
Emittente
GLOBENEWSWIRE
1.00
0
24/02/2026
Medicina Salute Benessere
Finanza
Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases
Fonte
Alveus Therapeutics Inc
Emittente
GLOBENEWSWIRE
1.00
0
23/01/2026
Medicina Salute Benessere
Annunci Economici
Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity
Fonte
Alveus Therapeutics Inc
Emittente
GLOBENEWSWIRE
1.00
0
08/01/2026
Medicina Salute Benessere
Finanza
Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases
Fonte
Alveus Therapeutics Inc
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0